Time in range

Is this the new gold standard?

30 November 2020


Thanks for registering

We have sent you a confirmation email and look forward to welcoming you online. We will send you a reminder email closer to the start of the broadcast.

This promotional meeting is organised and funded by Novo Nordisk and Abbott.
Marketing and organisational support has been provided by OmniaMed Communications.
The information presented at this meeting is intended for UK-based healthcare professionals.
Adverse event reporting information and Prescribing Information will be available at this meeting.

Prescribing information for Fiasp® (insulin aspart) can be found here.

Prescribing information for Tresiba® (insulin degludec) can be found here.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055).
Calls may be monitored for training purposes.

Job code: UK20DI00284; ADC-27961. Date of preparation: October 2020

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.